| 引用本文:程晔，周玟.中药“扶正消瘤方”联合射频消融术治疗老年晚期非小细胞肺癌的临床效果和预后[J].世界中医药,2017,(12):. |
|
| 中药“扶正消瘤方”联合射频消融术治疗老年晚期非小细胞肺癌的临床效果和预后 |
| Clinical Study and Prognosis Analysis of Fuzheng Anti-tumor Prescription Combined with Radiofrequency Ablation in Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer |
| 投稿时间：2017-06-05 |
| DOI：10.3969/j.issn.1673-7202.2017.12.016 |
| 中文关键词: 扶正消瘤方 射频消融术 生存率 非小细胞肺癌 |
| English Keywords:Fuzheng anti tumor prescription Radiofrequency ablation Life therapy Survival rate Non-small cell lung cancer |
| 基金项目:江苏省卫生厅预防医学科研课题（Y2013021） |
|
| 摘要点击次数: 1156 |
| 全文下载次数: 1006 |
| 中文摘要: |
| 目的：探讨中药“扶正消瘤方”联合射频消融术（RFA）治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效。方法：选取2011年2月至2013年5月江苏省肿瘤医院收治的NSCLC患者136例，随机分为观察组（n＝68例）及对照组（n＝68例）。对照组给予射频消融术（RFA）治疗；观察组在上述基础上联合中药“扶正消瘤方”治疗。2组疗程均为2个月。评价2组患者近期疗效、近3年生存率、生命质量（QOL）和体力状况（PS）评分改善情况，观察治疗期间2组不良反应发生率。结果：对照组疾病有效率为60.3%，观察组治疗后疾病有效率为88.2%，差异有统计学意义（P<0.05）。术后2周2组QOL、PS评分比较，差异无统计学意义（P>0.05）；术后1个月、3个月观察组QOL、PS评分改善情况均明显优于对照组，差异有统计学意义（P<0.05）。治疗后，观察组咳嗽、气短、神疲乏力、胃纳差、失眠等临床症状评分均明显低于对照组（P<0.05）。观察组术后胸痛、胸腔积液、咯血、发热、消化道不良反应发生率明显低于对照组（P<0.05）。观察组1年生存率明显高于对照组，差异有统计学意义（P<0.05）；2组2、3年生存率比较，差异无统计学意义（P>0.05）。结论：扶正消瘤方联合RFA治疗老年晚期NSCLC近期疗效显著，能改善体力状况和临床症状，提高患者生命质量，且创伤小，安全性高；远期在延长生存率方面表现出优势。 |
| English Summary: |
| To study clinical study and prognosis analysis of Fuzheng anti tumor prescription combined with radiofrequency ablation in treatment of elderly patients with advanced non-small cell lung cancer.Methods:A total of 136 patients with NSCLC in our hospital from February 2011 to May 2013 were randomly divided into the observation group (n＝68 cases) and the control group (n＝68 cases).The control group was treated with radiofrequency catheter ablation (RFA), and the observation group was treated in combination with “Fuzheng anti tumor prescription” on the basis of above treatment.The two groups were treated for 2 months.The short-term efficacy, survival rate, quality of life (QOL) and physical condition (PS) score of two groups were evaluated, and the incidence of adverse reactions in the two groups was observed during the treatment period of 3 years.Results:The remission rate of the control group was 60.3%, and the remission rate of the observation group was 88.2%.The difference between the two groups was statistically significant (P<0.05).2 weeks after operation, there was no significant difference between the two groups in QOL and PS scores (P>0.05).After 1 months and 3 months, the improvement of QOL and PS scores in the observation group was significantly better than that in the control group, and the difference was statistically significant (P<0.05).After treatment, the scores of cough, shortness of breath, lassitude, appetite, insomnia and other clinical symptoms in the observation group were significantly lower than those in the control group (P<0.05).The incidence of chest pain, pleural effusion, hemoptysis, fever and digestive tract adverse reactions in the observation group was significantly lower than that in the control group (P<0.05).The 1 year survival rate of the observation group was significantly higher than that of the control group, and the difference was significant (P<0.05).There was no significant difference in the 2 and 3 year survival rates between the two groups (P>0.05).Conclusion:The short-term efficacy of Fuzheng anti tumor prescription combined with RFA in the treatment of advanced NSCLC in the elderly is very significant, can improve the patient's physical condition and clinical symptoms, and improve the quality of life of patients with small trauma and high safety.Long-term treatment has obvious advantages in prolonging survival rate, and it is worthy of clinical promotion. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
